A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular
Metabolic Disease
Dyslipidemias
Lipid Disorder
Hypertriglyceridemia
Heterozygous Familial Hypercholesterolemia (HeFH)
Homozygous Familial Hypercholesterolemia (HoFH)
Severe Hypertriglyceridemia (sHTG)
Mixed Hyperlipemia
Hypercholesterolaemia

Interventions

DRUG: CTX310

Sponsor

CRISPR Therapeutics AG